Retool Awarded 2025 Databricks Emerging Partner of the Year
'Databricks has redefined the modern data stack, and Retool is proud to be the app layer that helps enterprises turn that data into action,' said David Hsu, co-founder and CEO of Retool. 'This award is a testament to our shared vision where, with our help, developers drive the future of work, powered by AI.'
"These awards are always one of my favorite moments of the year, and we are thrilled to name Retool the 2025 Databricks Emerging Partner of the Year," said Roger Murff, VP of Technology Partners at Databricks. "As more enterprises seek to build domain-specific AI applications, Retool's partnership with Databricks is essential to helping these organizations leverage the right data to build AI agents that drive real business outcomes."
This award reflects growing recognition of how organizations are transforming operations through AI-powered automation. Our Databricks integration addresses this need by giving teams a direct path from raw data to business outcomes—whether that's operational dashboards for real-time insights or autonomous agents handling complex workflows. The platform handles the technical complexity of security and scale, so developers can focus on solving business problems rather than infrastructure challenges.
About Retool
Retool is the application layer for AI and leading platform for internal software development, trusted by over 10,000 companies worldwide, including Amazon, Stripe, Brex, and Orangetheory Fitness. Using Retool, developers deploy sophisticated apps and agents dramatically faster without sacrificing quality or control, combining powerful building blocks with the flexibility of custom code. The company's model-agnostic approach lets teams select the optimal AI capabilities for each use case while maintaining enterprise-grade security and scalability. To learn more, visit https://retool.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Trump pauses export controls to bolster China trade deal, FT says
(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added.
Business Wire
26 minutes ago
- Business Wire
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
LEIDEN, Netherlands--(BUSINESS WIRE)-- Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros, and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' Share The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. 'The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases,' said Stefano Portolano, Chief Executive Officer at Azafaros. 'We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy.' About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Entrepreneur
26 minutes ago
- Entrepreneur
UBQT Named Official Networking Platform for Step Conference San Francisco
You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Step Conference, a tech event for emerging markets, has partnered with UBQT, an AI-powered platform enabling real-life catchups within professional communities, as its official networking platform for the upcoming San Francisco edition. UBQT will empower Step San Francisco (Step SF) attendees to plan professional catchups, connect across borders, and deepen relationships throughout the event. UBQT, co-founded by Lara Varjabedian, Jonathan L. Hasson, and I.Q. Sayed, is the tool of choice for community owners, event organisers, and corporates looking to drive engagement and social cohesion through meaningful in-person connections. With features that allow attendees to sync diaries, receive smart nudges when peers are nearby, and streamline spontaneous or planned catchups, UBQT ensures real-life moments are easy and frequent. This partnership reflects Step SF's commitment to building authentic, cross-border collaboration, and UBQT's mission to tech-enable communities to unlock social capital. Finding the 'human' in a digital world Screen fatigue and digital fragmentation has left many of us craving the energy and spontaneity of real-life interaction. UBQT empowers this, allowing organisations to drive high-quality engagement in real life. Attendees and speakers at Step SF will: - Receive smart catchup recommendations when someone from your network is nearby or planning to be nearby soon, - Align calendars and travel plans to coordinate catchups, - Make the most of the event by discovering the most relevant fellow attendees - founders, investors and ecosystem enablers, - Stay connected with the community well beyond the event. "UBQT goes beyond simply enabling great networking at Step SF. It empowers our attendees to connect meaningfully, not just during the event, but well beyond it," said Ray Dargham, co-founder and CEO at Step. "It's not just another event app; it's a true community engagement platform. We're proud to bring this experience to our San Francisco network." Related: Nurturing Connections: UBQT Co-Founders Jonathan L. Hasson And Lara Varjabedian
